AL2021-03-05T09:31:34+00:00

AL Amyloidosis

Light chain amyloidosis (AL amyloidosis) is a clonal plasma cell disorder that is characterized by multi-organ dysfunction as a result of deposition of immunoglobulin monoclonal light chain–derived amyloid fibrils, despite a low burden of plasma cells.

For the Australian peer-reviewed guide to the diagnosis and management of AL amyloidosis please go to the (Myeloma Medical and Scientific Advisory Group’s) clinical practice guideline
Management of Systemic AL Amyloidosis”.

These guidelines were prepared to provide Australian clinicians with a current, practical and evidence-based approach to the management of AL amyloidosis and were last updated in September 2019.